Full Archive

A Mesothelioma Blood Test Could Improve Patient Quality of Life

December 3, 2021
Categories: , , ,

A blood test for mesothelioma could help increase the time between CT scan appointments. The typical way doctors test to see if a treatment is working is called mRECIST, which utilizes CT scans and other measurements. CT scans are expensive though and can lead to larger exposure to ionizing radiation than someone might expect. The…

Follow Up Care for Mesothelioma

November 19, 2021
Categories: , , , , ,

Follow-up care is crucial for treating mesothelioma patients. A study out of the United Kingdom found that when patients receive follow-up care, more input from their caregivers, continuity, and more timely information was necessary. The study involved three National Health Service facilities in England. Two of the centers were secondary care facilities while the other…

SQAP Used Alongside Radiation to Treat Mesothelioma

November 12, 2021
Categories: , , , ,

A chemical that makes cancer cells more sensitive to radiation could potentially help patients with mesothelioma. Radiotherapy utilizes ionizing radiation to damage the DNA of cancer cells, which affects their ability to reproduce and form tumors. Radiation is not always used for mesothelioma patients because mesothelioma cells can be immune to radiation and it can…

Researchers Could Target Neuron Cells to Fight Mesothelioma

October 29, 2021
Categories: , , , ,

Researchers have potentially found a new way to treat cancer by targeting nerve cells.  Researchers at Technion, the Israel Institute of Technology, conducted the study that is now published in the Science Advances journal. The research targets neurons, which promote tumor growth. The researchers assumed that once tumor nerve cells were targeted with a damaging…

Quinacrine Combined with Cisplatin Can Help Fight Mesothelioma Cancer Cells

October 15, 2021
Categories: , , , , ,

Mesothelioma patients with a gene mutation could benefit greatly from using an anti-malaria drug called quinacrine. Quinacrine is known by the brand name Atabrine. For a long time, it was the primary anti-malaria drug, but it has been replaced by the preferred chloroquine. Researchers at Penn State found that quinacrine shows great cytotoxicity when used…

Patients with Mesothelioma Don’t Always Have Access to the Best Care

October 8, 2021
Categories: , , , , ,

Unfortunately, there is a lack of equality when it comes to treating mesothelioma patients because access to care can be very inconsistent. Patients might not have access to a high-volume academic hospital that treats mesothelioma patients, so they are not receiving the proper care that some people might receive. Patients with mesothelioma from different areas…

A Cancer Fighting Gel Can Help Mesothelioma Patients

October 1, 2021
Categories: , , , ,

A cancer fighting gel that is applied directly to tumors could help mesothelioma patients. Researchers in Maryland tested the treatment on animals with mesothelioma tumors. The tumors responded even after one application. The gel could be used alone or could be used while doctors are performing surgery on mesothelioma. It could change the future of…

MRIs vs CT Scans for Imaging Mesothelioma

September 24, 2021
Categories: , ,

MRI scans could be better than CT scans for diagnosing and monitoring disease response in pleural mesothelioma patients. An Italian study is looking at the two imaging techniques to compare the effectiveness of each one and is publishing results in the online medical journal Cancers. Computed tomography scans (CT) are currently the most popular way…

Ramucirumab and Gemcitabine are Showing Promising Results as a Second Line Treatment for Pleural Mesothelioma

September 17, 2021
Categories: , , , , , , ,

Combining the drug ramucirumab with the chemotherapy drug gemcitabine is showing to be a successful second line treatment for pleural mesothelioma. Ramucirumab is a type of immunotherapy drug called a monoclonal antibody, which targets and restricts proteins that stimulate blood vessel growth in tumors. The Lancet Oncology published the results of the Italian study involving…

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

September 10, 2021
Categories: , , , , , ,

Primary Outcome Measures Major Pathologic (Disease) Response of Tumor to Nivolumab Combined with Ipilimumab Before Surgery [ Time Frame: 24 months ] The response of participant’s tumor to treatment with nivolumab and ipilimumab before surgery by analyzing tissue samples collected from participant during surgery for the presence of cancerous tumour cells. Major pathologic response will be defined as tissue…